Recently, a meta-analysis (Ferrara et al., 2020) shows that single-agent ICI in patients with NSCLC and PD-L1 ≥50% probably lead to a higher OS rate (hazard ratio (HR) 0.68, 95% confidence interval (CI) [0.60–0.76]) and may improve PFS (HR 0.68, 95% CI [0.52–0.88]) and overall response rate (ORR) (risk ratio (RR) 1.40, 95% CI [1.12–1.75]) when compared to platinum-based chemotherapy and may also lead to a lower rate of adverse events (AEs) (RR 0.41, 95% CI [0.33–0.50]) and higher health-related quality of life (HRQoL) (RR 1.51, 95% CI [1.08–2.10]). The gene discussed is CD274; the disease is non-small cell lung carcinoma.